- Conditions
- Hypereosinophilia, Hypereosinophilic Syndrome
- Interventions
- mepolizumab
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 11
- States / cities
- San Diego, California • Denver, Colorado • Bethesda, Maryland + 8 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–8
of 8
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Hypereosinophilic Syndrome
- Interventions
- mepolizumab
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2010
- U.S. locations
- 10
- States / cities
- San Diego, California • Denver, Colorado • Bethesda, Maryland + 7 more
- Conditions
- Eosinophilia, Hypereosinophilic Syndrome
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 1 Year to 100 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2005
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Eosinophilia, Hypereosinophilic Syndrome, Leukocyte Disorder, Hematologic Diseases
- Interventions
- prednisone
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 7 Years to 100 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2020
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Eosinophilic Granulomatosis With Polyangiitis (EGPA), Hypereosinophilia Syndrome (HES)
- Interventions
- Benralizumab
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 3
- States / cities
- Aurora, Colorado • Cincinnati, Ohio • Highland Hills, Ohio
- Conditions
- Immune System Diseases, Eosinophilia, Helminthiasis, Hypersensitivity, Parasitic Disease
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 1 Year to 100 Years
- Enrollment
- 800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1997
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Hypereosinophilic Syndrome
- Interventions
- SCH55700
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- Not listed
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2003
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Respiratory System Agents, Anti-Asthmatic Agents, Hematologic Diseases, Leukocyte Disorders, Hypereosinophilia
- Interventions
- benralizumab, Placebo
- Drug · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2023
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland